首页
登录
职称英语
Celebrate. Celebrate. Physicians are delighted with a Food and Drug Administ
Celebrate. Celebrate. Physicians are delighted with a Food and Drug Administ
游客
2023-12-27
55
管理
问题
Celebrate. Celebrate. Physicians are delighted with a Food and Drug Administration(FDA)advisory panel’s recommendation earlier this year that Vioxx and its cousins Bextra and Celebrex(all medicines known as Cox-2 inhibitors)should remain on the market, despite evidence they increase heart disease risk in some people. The panelists reached their decision after weighing all the data and concluding the benefits of these pain-relieving drugs outweighed the risks.
Specifically, these scientists acknowledged that, for some patients, these prescription drugs were uniquely effective in reducing pain from arthritis and other causes. For others—concerned about ulcers associated with aspirin and other OTC analgesics—the Cox-2 inhibitors offered the advantage of minimizing potentially serious effects of stomach irritation.
Now is an appropriate time for everyone to take a fresh look at the benefit-risk equation for Vioxx and the other Cox-2 inhibitors.
The risks— increased risk of heart disease in some who use the drugs—have been well publicized. Much less publicity has been given to a spectrum of real and potential benefits that go way beyond reduced risk of stomach irritation. These little-discussed benefits would have been lost, perhaps permanently-had Vioxx, Bextra and Celebrex been driven from shelves in pursuit of perfect safety, an unattainable goal.
For example, there is substantial evidence Cox-2 inhibitors can reduce development of colon polyps, which may become colon canceL Indeed. Celebrex is FDA-approved for those genetically prone to colon cancer. Ironically, the 2004 study that revealed the elevated heart attack risk of Vioxx was primarily designed to further establish the drug’s effectiveness in protecting against colon cancer. And while the results of that interrupted trial have not yet been published, there is good reason to believe they will confirm the protective effects against colon cancer established in research over the last 10 years.
At the time of its withdrawal from the market last fall, studies of Vioxx as well as the other Cox-2 drugs suggest that they had other anti-cancer properties as well, possibly reducing the risk of malignancies of a number of sites, including the lung and esophagus.
Had these drugs been dismissed, their untapped promise for prevention would have evaporated well before it was evaluated and applied to save lives. Fortunately, cooler and wiser heads prevailed. [br] When Cox-2 inhibitors were banned from sale, ______.
选项
A、no research had been done about their effects
B、some studies demonstrated their usefulness
C、their risks were not well known to the public
D、some patients complained about the decision
答案
B
解析
根据文中内容可知,当发现Cox-2抑制剂会增大患心脏病的危险时,Cox一2抑制剂被禁止销售,但一些研究人员的研究结果却显示,Cox-2抑制剂在许多领域都会发挥积极效用,所以应该选择B。
转载请注明原文地址:https://www.tihaiku.com/zcyy/3308693.html
相关试题推荐
Iamdelightedthatweareonceagaincelebratingtheachievementsofourcol
Iamdelightedthatweareonceagaincelebratingtheachievementsofourcol
IamdelightedtoonceagainbestandingbeforeyouaswecelebrateCanadaDa
Iamdelightedtobeheretodayatthisschoolofhighachievers.Firstofa
Washington:TheBushadministrationhas【C1】______forthefirsttimethatit
Washington:TheBushadministrationhas【C1】______forthefirsttimethatit
Washington:TheBushadministrationhas【C1】______forthefirsttimethatit
Washington:TheBushadministrationhas【C1】______forthefirsttimethatit
Washington:TheBushadministrationhas【C1】______forthefirsttimethatit
Washington:TheBushadministrationhas【C1】______forthefirsttimethatit
随机试题
对发生法律效力的仲裁裁定,一方当事人不履行,另一方当事人可以向下列哪个部门申请强
慢性盘状红斑狼疮在口腔黏膜的好发部位是A.上唇唇红 B.上腭黏膜 C.颊部黏
根据《公司法》的规定,公司章程对下列哪些人员具有约束力() Ⅰ员工
确定具体的投资品种和各种资产的投资比例属于证券组合管理中的一个重要步骤,该步骤也
姜黄与郁金的药用部位分别为()。A.根茎、块根B.鳞茎、块根C.块根、块茎D.
在进行临床研究之前,研究方案必须经过医院的哪个部门批准A.医院党委办公室B.医院
面部“危险三角区”的疖若处理不当,可引起的严重后果是A:急性蜂窝织炎 B:脓毒
工程监理单位在实施监理过程中,发现存在严重的安全事故隐患时,应当要求施工单位()
克林霉素与红霉素合用()A.药理作用拮抗 B.不良反应叠加 C.后者血药
下列哪项不是低钾血症的病因A.长期进食不足 B.应用利尿剂 C.钾盐补充不足
最新回复
(
0
)